hemotherapy remains one of the most effective therapeutic strategies for the treatment of breast cancer, although the number of patients who don’t respond to it, or relapse despite it, is considerable. This treatment is especially crucial for people with triple-negative breast cancer, defined by the lack of estrogen and progesterone receptors and the human epidermal growth factor receptor 2 (HER2). These patients, dependent on chemotherapy treatment, have poor prognoses due to the inherent resistance of their tumors to chemotherapy drugs. They also present an increased risk of recurrence. As such, understanding the underlying mechanisms of drug resistance is essential to improved tumor treatment and patient survival.
Researchers focused on methylation-controlled J protein (MCJ), a negative regulator of mitochondria